Loading...
Neurologists frequently see patients with Guillain-Barré syndrome (GBS) who reach a nadir and start to improve but then do not continue to improve as expected. Some patients' conditions fluctuate, leading to additional courses of treatment. Some stop improving. Some begin to decline again and may not respond to intravenous immunoglobulin (IVIG) or plasma exchange, the two treatments proven effective for GBS. The clinician is often left to ask, “Is this really GBS, or is it something else?” Using data from ongoing prospective studies of GBS in the Netherlands, researchers prospectively compared clinical, biologic, and electrophysiologic features in patients who ultimately were diagnosed with either GBS treatment-related fluctuations (GBS-TRF…